{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T05:55:33Z","timestamp":1726206933765},"reference-count":29,"publisher":"SLACK, Inc.","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatr Ann"],"published-print":{"date-parts":[[2003,10]]},"DOI":"10.3928\/0090-4481-20031001-08","type":"journal-article","created":{"date-parts":[[2014,5,27]],"date-time":"2014-05-27T17:45:25Z","timestamp":1401212725000},"page":"671-676","source":"Crossref","is-referenced-by-count":12,"title":["Pharmacologic Therapies Aid Treatment for Autism"],"prefix":"10.3928","volume":"32","author":[{"given":"Ronald L","family":"Lindsay","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael G","family":"Aman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2308","reference":[{"key":"e_1_3_1_2_1","doi-asserted-by":"crossref","unstructured":"1 . Fombonne E du Mazaubrun C. Prevalence of infantile autism in four French regions. Soc Psychiatry Psychiatr Epidemiol. 1992;27(4):203-210.","DOI":"10.1007\/BF00789007"},{"key":"e_1_3_1_3_1","doi-asserted-by":"crossref","unstructured":"2. Aman MG Van Bourgonthen ME Wolford PL Sarphare G. Psychotropic and anticonvulsant drugs in subjects with autism: prevalence and patterns of use. J Am Acad Child Adolesc Psychiatry. 1995;34(12):1672-1681.","DOI":"10.1097\/00004583-199512000-00018"},{"key":"e_1_3_1_4_1","unstructured":"3. McDougle CJ Scahill L McCracken JT et al. Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. Background and rationale for an initial controlled study of risperidone. Child Adolesc Psychiatr Clin N Am. 2000;9(1):20 1-224."},{"key":"e_1_3_1_5_1","doi-asserted-by":"crossref","unstructured":"4. Langworthy-Lam KS Aman MG. Van Bourgonthen ME. Prevalence and patterns of use of psychoactive medicines in individuals with autism in the Autism Society of North Carolina. J Child Adolesc Psychopharmacol. 2002;12(4):31 1-321.","DOI":"10.1089\/104454602762599853"},{"key":"e_1_3_1_6_1","doi-asserted-by":"crossref","unstructured":"5. Scahill L. McCracken J McDougle CJ. et al. Methodological issues in designing a multisite trial of risperidone in children and adolescents with autism. J Child Adolesc Psychopharmacol. 2001 ; 1 1 (4):377-388.","DOI":"10.1089\/104454601317261555"},{"key":"e_1_3_1_7_1","unstructured":"6. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington DC: APA; 1994."},{"key":"e_1_3_1_8_1","unstructured":"7. World Health Organization. The ICD-IO Classification of Mental and Behavioural Disorders: Diagnostic Criteria for Research. Geneva Switzerland: WHO; 1993."},{"key":"e_1_3_1_9_1","doi-asserted-by":"crossref","unstructured":"8. Aman MG. Stimulant drugs in the developmental disabilities revisited. Journal of Developmental and Physical Disabilities. 1996;8(4):347-365.","DOI":"10.1007\/BF02578400"},{"key":"e_1_3_1_10_1","unstructured":"9. Aman MG Langworthy KS. Pharmacotherapy for hyperactivity in children with autism and other pervasive developmental disorders. J Autism Dev Disord. 2OO0;3O(5):45 1 -459."},{"key":"e_1_3_1_11_1","unstructured":"10. Rush AJ Frances A. The Expert Consensus Guideline Series: Treatment of psychiatric and behavioral problems in mental retardation. Am J Ment Retardation. 2000;105(3):159-228."},{"key":"e_1_3_1_12_1","doi-asserted-by":"crossref","unstructured":"11. Anderson LT Campbell M Adams P et al. The effects of Haloperidol on discrimination learning and behavioral symptoms in autistic children. J Autism Dev Disord. 1989;19(2):227-239.","DOI":"10.1007\/BF02211843"},{"key":"e_1_3_1_13_1","doi-asserted-by":"crossref","unstructured":"12. Campbell M Armenteros JL Malone RP et al. Neuroleptic-related dyskinesias in autistic children: a prospective longitudinal study. J Am Acad Child Adolesc Psychiatry. 1997;36(6):835-843.","DOI":"10.1097\/00004583-199706000-00022"},{"key":"e_1_3_1_14_1","doi-asserted-by":"crossref","unstructured":"13. Schreibman L. Intensive behavioral\/psychoeducational treatments for autism: research needs and future directions. J Autism Dev Disord. 2000;3O(5):373-378.","DOI":"10.1023\/A:1005535120023"},{"key":"e_1_3_1_15_1","doi-asserted-by":"crossref","unstructured":"14. Aman MG Singh NN. Aberrant Behavior Checklist Manual. East Aurora New York: Slossen Educational Publications; 1986.","DOI":"10.1037\/t10453-000"},{"key":"e_1_3_1_16_1","doi-asserted-by":"crossref","unstructured":"15. Aman MG Singh NN Stewart AW Field CJ. The aberrant behavior checklist: a behavior rating scale for tf\u00bbe assessment of treatment effects. Am J Ment Defic. 1985;89(5):485491.","DOI":"10.1037\/t10453-000"},{"key":"e_1_3_1_17_1","doi-asserted-by":"crossref","unstructured":"16. Marshburn EC Aman MG. Factor validity and norms for die aberrant behavior checklist in a community sample of children with mental retardation. \/ Autism Dev Disord. 1992;22(3):357-373.","DOI":"10.1007\/BF01048240"},{"key":"e_1_3_1_18_1","unstructured":"17. McCracken JT McGough J Shah B et al. and the Research Units on Pediatric Psychopharmacology Autism Network. Risperidone in children with autism and serious behavioral disturbances. N Eng J Med. 2002(5);347:3 14-321."},{"key":"e_1_3_1_19_1","unstructured":"18. Research Units on Pediatric Psychopharmacology Autism Network. Risperidone treatment of autistic disorder: longer term benefits and blinded discontinuation after six months. J Dev Behav Pediatr. 2002;23(4):396. Review."},{"key":"e_1_3_1_20_1","doi-asserted-by":"crossref","unstructured":"19. Aman MG Arnold LE Armstrong SC. Review of serotonergic agents and perseverative behavior in patients with developmental disabilities. Ment Retard Dev Disabil Res Rev. 1999;5:279-289.","DOI":"10.1002\/(SICI)1098-2779(1999)5:4<279::AID-MRDD5>3.0.CO;2-6"},{"key":"e_1_3_1_21_1","unstructured":"20. Campbell M. The effect of neuroleptics on cognition and diagnosis and their influence on stereotypies. J Ment Defic Res. 1 987;3 1 (Pt 2):220-225."},{"key":"e_1_3_1_22_1","doi-asserted-by":"crossref","unstructured":"21. Aman MG Madrid A. Atypical antipsychotics in persons with developmental disabilities. Ment Retard Dev Disabil Res Rev. 1999;5(4):253-263.","DOI":"10.1002\/(SICI)1098-2779(1999)5:4<253::AID-MRDD2>3.0.CO;2-R"},{"key":"e_1_3_1_23_1","unstructured":"22. Arnold LE Vitiello B Chuang S et al. Parent-defined target symptoms respond to risperidone in RUPP Autism Network study: a customer approach to subjecthood in clinical trials. \/ Am Acad Child Adolesc Psychiatry. In press."},{"key":"e_1_3_1_24_1","doi-asserted-by":"crossref","unstructured":"23. Aman MG. Efficacy of psychotropic drugs for reducing self-injurious behavior in the developmental disabilities. Ann Clin Psychiatry. 1993;5(3):171-188.","DOI":"10.3109\/10401239309148981"},{"key":"e_1_3_1_25_1","doi-asserted-by":"crossref","unstructured":"24. Muris P Steerneman P Merckelbach H Holdrinet I Meesters C. Comorbid anxiety symptoms in children wi\u00fci pervasive developmental disorders. J Anxiety Disord. 1998;12(4):387-393.","DOI":"10.1016\/S0887-6185(98)00022-X"},{"key":"e_1_3_1_26_1","doi-asserted-by":"crossref","unstructured":"25. McDougle CJ Naylor ST Cohen DJ et al. A double-blind placebo-controlled study of fluvoxamine in adults with autistic disorder. Arch Gen Psychiatry. 1996;53(11):10011008.","DOI":"10.1001\/archpsyc.1996.01830110037005"},{"key":"e_1_3_1_27_1","doi-asserted-by":"crossref","unstructured":"26. Cook EH Jr; Rowlett R Jaselskis C. Leventhal BL. Fluoxetine treatment of children and adults with autistic disorder and mental retardation. J Am Acad Child Adolesc Psychiatry. 1992;31(4):739-745.","DOI":"10.1097\/00004583-199207000-00024"},{"key":"e_1_3_1_28_1","doi-asserted-by":"crossref","unstructured":"27. Steingard RJ Zimnitzky B DeMaso DR Bauman ML Bucci JP. Sertraline treatment of transition-associated anxiety and agitation in children with autistic disorder. J Child Adolesc Psychopharmacol. 1997;7(1):9-15.","DOI":"10.1089\/cap.1997.7.9"},{"key":"e_1_3_1_29_1","doi-asserted-by":"crossref","unstructured":"28. Realmuto GM August GJ Garfinkel BD. Clinical effect of buspirone in autistic children. J Clin Psychopharmacol. 1989:9(2): 122- 125.","DOI":"10.1097\/00004714-198904000-00009"},{"key":"e_1_3_1_30_1","doi-asserted-by":"crossref","unstructured":"29. McCormick LH. Treatment with buspirone in a patient with autism. Arch Fam Med. 1997;6(4):368-370.","DOI":"10.1001\/archfami.6.4.368"}],"container-title":["Pediatric Annals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.healio.com\/doiresolver?doi=10.3928\/0090-4481-20031001-08","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T07:56:19Z","timestamp":1683100579000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.healio.com\/doi\/10.3928\/0090-4481-20031001-08"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,10]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2003,10]]}},"alternative-id":["10.3928\/0090-4481-20031001-08"],"URL":"https:\/\/doi.org\/10.3928\/0090-4481-20031001-08","relation":{},"ISSN":["0090-4481","1938-2359"],"issn-type":[{"value":"0090-4481","type":"print"},{"value":"1938-2359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,10]]}}}